{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"203.93","value":"212.4"}]}],"title":"Stage 3 [N=17]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"118.3","value":"195.5"}]}],"title":"Stage 4 [N=25]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"107.1","value":"145.7"}]}],"title":"Stage 5 [N=407]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"718"}],"units":"Participants"}],"description":"Participants achieved Intact Parathyroid Hormone (iPTH) levels within the target range of Kidney Disease Quality Outcome Initiative (K/DOQI) treatment guidelines (Chronic Kidney Disease (CKD), stage 3: 35 to 70 pg/mL; CKD stage 4: 70 to 110 pg/mL; CKD stage 5: 150 to 300 pg/mL).","dispersionType":"Standard Deviation","groups":[{"description":"Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, not treated with paricalcitol for at least 6 months prior inclusion in this study, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.","id":"OG000","title":"Paricalcitol"}],"paramType":"MEAN","populationDescription":"Participants with a determined chronic kidney disease (CKD) stage","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Time to Achieve Target Range of Intact Parathyroid Hormone (iPTH) Levels Within the Target Range After 12 Months","type":"PRIMARY","unitOfMeasure":"days"}